Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $62.56 Consensus Target Price from Brokerages
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned a consensus rating of “Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to […]
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned a consensus rating of “Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to […]
